Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (8): 506-512.
Received:2018-10-11
Revised:2018-10-11
Online:2018-08-20
Published:2018-10-11
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
| [1] Moher David,Liberati Alessandro,Tetzlaff Jennifer, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J] .PLoS Med., 2009, 6(7): e1000097. [2] Gray JAM.Evidence-based healthcare.How to make health policy and management decisions[M] .Churchill Livingstone, 2001. [3] Sackett D L,Wennberg J E.Choosing the best research design for each question[J]. BMJ, 1997, 315(7123): 1636. [4] Ioannidis John P A. Adverse events in randomized trials: neglected, restricted, distorted, and silenced[J] .Arch. Intern. Med., 2009, 169(19): 1737-1739. [5] Singh Sonal,Loke Yoon K.Drug safety assessment in clinical trials: methodological challenges and opportunities[J].Trials, 2012, 13(1): 138. [6] Papanikolaou Panagiotis N,Ioannidis John P A. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials[J]. Am. J. Med., 2004, 117(8): 582-589. [7] Pitrou Isabelle,Boutron Isabelle,Ahmad Nizar, et al.Reporting of safety results in published reports of randomized controlled trials[J]. Arch. Intern. Med., 2009, 169(19): 1756-1761. [8] Loke Y K,Derry S.Reporting of adverse drug reactions in randomised controlled trials-a systematic survey[J]. BMC Clin Pharm- acol, 2001, 1(1): 3. [9] Ioannidis J P,Lau J.Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas[J]. JAMA, 2001, 285(4): 437-443. [10] Yazici Yusuf.Some concerns about adverse event reporting in randomized clinical trials[J]. Bull NYU Hosp Jt Dis, 2008, 66(2): 143-145. [11] Ernst E,Pittler M H.Assessment of therapeutic safety in systematic reviews: literature review[J]. BMJ, 2001, 323(7312): 546. [12] Zorzela Liliane,Golder Su,Liu Yali, et al.Quality of reporting in systematic reviews of adverse events: systematic review[J]. BMJ, 2014, 348: f7668. [13] Golder Su,Loke Yoon K,Zorzela Liliane.Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011[J]. J Clin Epidemiol, 2013, 66(3): 253-260. [14] McIntosh Heather M,Woolacott Nerys F,Bagnall Anne-Marie. Assessing harmful effects in systematic reviews[J]. BMC Med Res Methodol, 2004, 4(1): 19. [15] Cornelius V R,Perrio M J,Shakir S A W, et al. Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality[J]. Pharmacoepidemiol Drug Saf, 2009, 18(12): 1223-1231. [16] Loke Yoon K,Golder Su P,Vandenbroucke Jan P.Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources[J]. Ther Adv Drug Saf, 2011, 2(2): 59-68. [17] Chou Roger, Fu Rongwei,Carson Susan, et al.Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions[J]. J Clin Epidemiol, 2007, 60(1): 18-28. [18] Chou Roger,Helfand Mark.Challenges in systematic reviews that assess treatment harms[J]. Ann. Intern. Med., 2005, 142(2): 1090-1099. [19] Hopewell Sally,Wolfenden Luke,Clarke Mike.Reporting of adverse events in systematic reviews can be improved: survey results[J]. J Clin Epidemiol, 2008, 61(6): 597-602. [20] Hernandez Adrian V,Walker Esteban,Ioannidis John P A et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone[J]. Am. Heart J., 2008, 156(1): 23-30. [21] Stroup D F,Berlin J A,Morton S C, et al.Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta- analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA, 2000, 283(15): 2008-2012. [22] Moher David,Schulz Kenneth F,Simera Iveta, et al.Guidance for developers of health research reporting guidelines[J]. PLoS Med., 2010, 7(2): e1000217. [23] Beller Elaine M,Glasziou Paul P,Altman Douglas G, et al.PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts[J]. PLoS Med., 2013, 10(4): e1001419. [24] Shamseer Larissa,Moher David,Clarke Mike, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation[J]. BMJ, 2015, 350(1): g7647. [25] Pilkington Karen,Boshnakova Anelia.Complementary medicine and safety: a systematic investigation of design and reporting of systematic reviews[J]. Complement Ther Med, 2012, 20(1-2): 73-82. [26] Murphy M K,Black N A,Lamping D L, et al. Consensus development methods,their use in clinical guideline development[J].Health Technol Assess, 1998, 2(3): i-iv, 1-88. [27] Higgins J P T, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011. www.cochrane-handbook.org. [28] Chou Roger,Aronson Naomi,Atkins David, et al.AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program[J].J Clin Epidemiol, 2010, 63(5): 502-512. [29] Ioannidis John P A,Evans Stephen J W,G tzsche Peter C, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement[J]. Ann. Intern. Med., 2004, 141(10): 781-788. [30] Loke Yoon K,Price Deirdre,Herxheimer Andrew, et al.Systematic reviews of adverse effects: framework for a structured approach[J].BMC Med Res Methodol, 2007, 7(1): 32. [31] Arbyn M,Kyrgiou M,Simoens C, et al.Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis[J]. BMJ, 2008, 337(7673): a1284. [32] Loke Yoon Kong,Jeevanantham Vinodh,Singh Sonal.Bisphosphonates and atrial fibrillation: systematic review and meta-analysis[J]. Drug Saf, 2009, 32(3): 219-228. [34] Banach Ryan,Boskovic Radinka,Einarson Thomas, et al.Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta- analysis of cohort studies[J]. Drug Saf, 2010, 33(1): 73-79. [35] Loke Yoon Kong,Kwok Chun Shing,Singh Sonal.Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies[J]. BMJ, 2011, 342(7799): d1309. [36] Agbabiaka Taofikat B,Pittler Max H,Wider Barbara, et al.Serenoa repens (saw palmetto): a systematic review of adverse events[J].Drug Saf, 2009, 32(8): 637-647. [37] Hammad Tarek A,Neyarapally George A,Pinheiro Simone P, et al.Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment[J].Clin Trials, 2013, 10(3): 389-397. [38] Michele Theresa M,Pinheiro Simone,Iyasu Solomon.The safety of tiotropium-the FDA's conclusions[J]. N. Engl. J. Med., 2010, 363(12): 1097-1099. [39] Anello C, O'Neill R T. Does research synthesis have a place in drug regulatory policy?[J].Clin Res Regul A., 1996,13:13-21. [40] Golder Su,Loke Yoon,McIntosh Heather M. Room for improvement? A survey of the methods used in systematic reviews of adverse effects[J]. BMC Med Res Methodol, 2006, 6(1): 3. [41] Golder Su,Loke Yoon K,Bland Martin.Unpublished data can be of value in systematic reviews of adverse effects: methodological overview[J]. J Clin Epidemiol, 2010, 63(10): 1071-1081. [42] Bangalore Sripal,Kumar Sunil,Wetterslev J rn, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials[J]. BMJ, 2011, 342(7805): d2234. [43] Golder Su,Loke Yoon,McIntosh Heather M. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects[J]. J Clin Epidemiol, 2008, 61(5): 440-448. [44] Derry S,Loke Y K,Aronson J K.Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials[J]. BMC Med Res Methodol, 2001, 1(1): 7. [45] Golder Su,Loke Yoon K.The contribution of different information sources for adverse effects data[J]. Int J Technol Assess Health Care, 2012, 28(2): 133-137. [46] Golder Su,Loke Yoon Kong.Failure or success of electronic search strategies to identify adverse effects data[J]. J Med Libr Assoc, 2012, 100(2): 130-134. [47] Bellis J R,Pirmohamed M,Nunn A J, et al.Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis[J]. Br J Anaesth, 2014, 113(1): 23-42. [48] Leombruno J P,Einarson T R,Keystone E C.The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events[J]. Ann. Rheum. Dis., 2009, 68(7): 1136-1145. [49] Albavera-Hernández Cidronio,Rodríguez Jorge M,Idrovo Alvaro J.Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials[J]. Clin Rehabil, 2009, 23(5): 394-407. [50] Rücker Gerta,Schwarzer Guido,Carpenter James, et al.Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells[J]. Stat Med, 2009, 28(5): 721-738. [51] Bradburn Michael J,Deeks Jonathan J, Berlin Jesse A, et al.Much ado about nothing: a comparison of the performance of meta- analytical methods with rare events[J]. Stat Med, 2007, 26(1): 53-77. [52] Sweeting Michael J,Sutton Alexander J,Lambert Paul C.What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data[J]. Stat Med, 2004, 23(9): 1351-1375. [53] Stijnen Theo,Hamza Taye H,Ozdemir Pinar.Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data[J]. Stat Med, 2010, 29(29): 3046-3067. [54] Mattishent K,Loke Y K.Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta- analysis[J]. Diabetes Obes Metab, 2016, 18(2): 135-141. [55] Saini Pooja,Loke Yoon K,Gamble Carrol, et al.Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews[J]. BMJ, 2014, 349(nov21): g6501. [56] Loke Yoon Kong,Mattishent Katharina.If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of securit[J]. CMAJ, 2015, 187(1): 15-16. [57] Kirkham Jamie J,Dwan Kerry M,Altman Douglas G, et al.The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews[J].BMJ, 2010, 340(7741): c365. [58] Page Matthew J,McKenzie Joanne E,Kirkham Jamie, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions[J].Cochrane Database Syst Rev, 2014. [59] Keus F,Wetterslev J,Gluud C, et al.Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials[J]. Am. J. Gastroenterol., 2009, 104(3): 546-551. [60] Chan An-Wen,Hróbjartsson A,Haahr Mette T, et al.Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles[J]. JAMA, 2004, 291(20): 2457-2465. [61] Scharf Orit,Colevas A Dimitrios.Adverse event reporting in publications compared with sponsor database for cancer clinical trials[J]. J. Clin. Oncol., 2006, 24(24): 3933-3938. [62] Mahoney Michelle R,Sargent Daniel J.Adverse-event rates: journals versus databases[J]. Lancet, 2007, 369(9557): 171-172. [63] Chan An-Wen,Krleza-Jeri Karmela,Schmid Isabelle, et al.Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research[J]. CMAJ, 2004, 171(7): 735-740. [64] Sterne Jonathan A C,Sutton Alex J,Ioannidis John P A, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials[J]. BMJ, 2011, 343(5): d4002. [65] Lau Joseph,Ioannidis John P A,Terrin Norma, et al. The case of the misleading funnel plot[J]. BMJ, 2006, 333(7568): 597-600. [66] Lathyris Dimitrios,Panagiotou Orestis A,Baltogianni Maria, et al.Safety of medical interventions in children versus adults[J]. Pediatrics, 2014, 133(3): e666-673. [67] Singh Sonal,Loke Yoon K,Enright Paul L, et al.Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials[J].BMJ, 2011, 342(7811): d3215. [68] Ioannidis John P A,Patsopoulos Nikolaos A,Rothstein Hannah R. Reasons or excuses for avoiding meta-analysis in forest plots[J].BMJ, 2008, 336(7658): 1413-1415. [69] Bain E S, Middleton P F, Crowther C A.Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review[J]. BMC Pregnancy Childbirth,2013,13:195. [70] Langendam Miranda W,Tiemersma Edine W,van der Werf Marieke J, et al. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review[J]. PLoS ONE, 2013, 8(1): e53599. [71] Jolivot Pierre-Alain,Hindlet Patrick,Pichereau Claire, et al.A systematic review of adult admissions to ICUs related to adverse drug events[J].Crit Care, 2014, 18(6): 643. [72] K tter Thomas,da Costa Bruno R,F ssler Margrit, et al. Metamizole- associated adverse events: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(4): e0122918. [73] Meyer-Massetti Carla,Cheng Christine M,Sharpe Bradley A, et al.The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?[J].J Hosp Med, 2010, 5(4): E8-16. [74] HILL A B.The Environment And Disease: Association Or Causation?[J] .Proc. R. Soc. Med., 1965, 58: 295-300. [75] Uppsala Monitoring Centre. World Health Organization causality assessment criteria.2015. who-umc.org. [76] Shuster Jonathan J,Jones Lynn S,Salmon Daniel A.Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death[J].Stat Med, 2007, 26(24): 4375-4385. [77] Shuster Jonathan J.Empirical vs natural weighting in random effects meta-analysis[J]. Stat Med, 2010, 29(12): 1259-1265. [78] Ioannidis John P A,Hozo Iztok,Djulbegovic Benjamin. Optimal type I and type II error pairs when the available sample size is fixed[J]. J Clin Epidemiol, 2013, 66(8): 903-910. [79] Fernández-Balsells M Mercè,Murad Mohammad Hassan,Lane Melanie, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis[J]. J. Clin. Endocrinol. Metab., 2010, 95(6): 2560-2575. [80] Hohl Corinne M,Kelly-Smith Carolyn H,Yeung Titus C, et al. The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review[J]. Ann Emerg Med, 2010, 56(2): 105-113. [81] Moher David,Glasziou Paul,Chalmers Iain, et al.Increasing value and reducing waste in biomedical research: who's listening?[J] .Lancet, 2016, 387(10027): 1573-1586. [82] Glasziou Paul,Altman Douglas G,Bossuyt Patrick, et al.Reducing waste from incomplete or unusable reports of biomedical research[J]. Lancet, 2014, 383(9913): 267-276. [83] Shamseer Larissa,Galipeau James,Turner Lucy, et al.Improving the reporting and usability of research studies[J]. Can J Anaesth, 2013, 60(4): 337-339. [84] Turner Lucy,Shamseer Larissa,Altman Douglas G, et al.Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review[J].Syst Rev, 2012, 1(1): 60. [85] Macleod Malcolm R,Michie Susan,Roberts Ian, et al.Biomedical research: increasing value, reducing waste[J]. Lancet, 2014, 383(9912): 101-104. |
| [1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
| [2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
| [3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
| [4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
| [5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
| [6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
| [7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
| [8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
| [9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
| [10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
| [11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
| [12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
| [13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
| [14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
| [15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
